Apontis Pharma AG (APPH) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.061x

Based on the latest financial reports, Apontis Pharma AG (APPH) has a cash flow conversion efficiency ratio of -0.061x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.94 Million ≈ $-2.27 Million USD) by net assets (€31.62 Million ≈ $36.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Apontis Pharma AG fund operations to measure how many days the company can operate on defensive assets alone.

Apontis Pharma AG - Cash Flow Conversion Efficiency Trend (2019–2024)

This chart illustrates how Apontis Pharma AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Apontis Pharma AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Apontis Pharma AG ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Zeder Investments Ltd JSE:ZED	0.180x
W5 Solutions AB ST:W5	-0.091x
Scope Fluidics SA WAR:SCP	-0.102x
Macrogen Inc KQ:038290	0.042x
Ann Joo Resources Bhd KLSE:6556	0.053x
C&G Hi Tech Co.Ltd KQ:264660	0.021x
Gan Ltd NASDAQ:GAN	-0.074x
Medtecs International Corporation Ltd DRC TW:9103	0.027x

Annual Cash Flow Conversion Efficiency for Apontis Pharma AG (2019–2024)

The table below shows the annual cash flow conversion efficiency of Apontis Pharma AG from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Apontis Pharma AG (APPH) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	€31.02 Million ≈ $36.26 Million	€-2.90 Million ≈ $-3.39 Million	-0.094x	+77.54%
2023-12-31	€30.26 Million ≈ $35.38 Million	€-12.60 Million ≈ $-14.73 Million	-0.416x	-257.05%
2022-12-31	€41.57 Million ≈ $48.60 Million	€11.02 Million ≈ $12.88 Million	0.265x	+214.37%
2021-12-31	€40.71 Million ≈ $47.60 Million	€3.43 Million ≈ $4.01 Million	0.084x	-79.90%
2020-12-31	€3.46 Million ≈ $4.04 Million	€1.45 Million ≈ $1.70 Million	0.420x	+917.97%
2019-12-31	€4.64 Million ≈ $5.43 Million	€-238.07K ≈ $-278.33K	-0.051x	--

About Apontis Pharma AG

XETRA:APPH Germany Drug Manufacturers - Specialty & Generic

Market Cap

$107.13 Million

€91.63 Million EUR

Market Cap Rank

#19624 Global

#1801 in Germany

Share Price

€11.00

Change (1 day)

+0.00%

52-Week Range

€10.75 - €11.05

All Time High

€26.90